Results 151 to 160 of about 922 (169)
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. [PDF]
N Engl J MedEMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Agrawal N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Zhu D, Dayanandan R, Arimoto R, Mayne KJ, Ng SYA, Sammons E, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney DZI, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Brueckmann M, Landray MJ, Baigent C, Haynes R, EMPA-KIDNEY Collaborative Group. +41 moreeuropepmc +1 more sourcePlasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.
JAMA OncolLeone G, Orlando F, Dutey-Magni P, Vainauskas O, Grist E, Ciani Y, Lall S, Thakali S, Wingate A, Wetterskog D, Sachdeva A, Sydes MR, McPhail N, Sreenivasan T, O'Sullivan JM, Clarke NW, Parmar MKB, Brown LC, James ND, Demichelis F, Attard G, STAMPEDE collaborators. +21 moreeuropepmc +1 more sourceSome of the next articles are maybe not open access.Related searches:
